Af­ter cov­er­age re­stric­tions for Alzheimer's drugs, bi­par­ti­san House bill would force CMS to re­view drugs in­di­vid­u­al­ly

When Bio­gen’s con­tro­ver­sial Alzheimer’s drug Aduhelm was hit with a na­tion­al de­ci­sion from CMS that re­strict­ed cov­er­age to on­ly ran­dom­ized tri­als, prac­ti­cal­ly guar­an­tee­ing a com­mer­cial …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER